Grufity logoGrufity logo

BGNE

201.86USD+7.29(+3.75%)Market Closed

BeiGene Ltd

Market Summary

USD201.86+7.29Market Closed
3.75%

BGNE Alerts

BGNE Stock Price

RSI Chart

Valuation

Market Cap

224.2B

Price/Earnings

-111.81

Price/Sales

209.81

Price/Cashflow

-138.39

MarketCap/EBT

-112.17

Price/Sales

Profitability

EBT Margin

-187.04%

Return on Equity

-37.82%

Return on Assets

-27.18%

Fundamentals

Revenue

Revenue (TTM)

1.2B

Revenue Y/Y

87.77%

Revenue Q/Q

13.48%

Earnings

Earnings (TTM)

-2.1B

Earnings Y/Y

-34.72%

Earnings Q/Q

2.43%

Price Action

52 Week Range

350.95
(Low)(High)

Last 7 days

15.4%

Last 30 days

13.1%

Last 90 days

21.0%

Trailing 12 Months

-41.6%

Financial Health

Current Ratio

4.54

Investor Care

Shares Dilution (1Y)

10.65%

Diluted EPS (TTM)

-1.62

Peers (Alternatives to BeiGene)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
13.24% 45.49%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.13% -41.64%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
3.50% 20.88%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
3.66% 57.19%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
9.35% 28.19%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
9.82% 47.16%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
11.31% 51.76%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-3.30% 6.13%
-18.85
63.29
26.15% -23.38%
3.8B
-
48.10% -29.78%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
6.14% -50.33%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-1.03% -49.23%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
27.64% 144.62%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
12.76% -3.22%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
42.27% -60.18%
-1.4
4.57
-43.57% -69.06%
16.0M
-
3.64% -84.06%
-0.46
19.11
-77.61% 5.14%

Financials for BeiGene

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue17.0%1,2501,0698771,1761,062
  S&GA Expenses4.5%1,2551,2021,103990892
  R&D Expenses4.8%1,6251,5511,5281,4591,384
Earnings Before Taxes-5.9%-2,116.88-1,998.72-1,921.70-1,438.59-1,333.76
Net Income-7.2%-2,148.93-2,005.23-1,914.12-1,413.35-1,300.45
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-8.8%6,7267,3788,0218,6465,286
  Current Assets-9.4%5,7496,3466,9487,6144,433
    Cash Equivalents-7.4%4,1974,5314,3474,3761,383
  Inventory10.9%291262246243151
  Net PPE7.7%682633625588451
  Goodwill0%00000
Liabilities-0.2%2,0712,0762,1362,4031,929
  Current Liabilities0.9%1,4111,3981,3761,6001,304
    LT Debt, Current15.9%4413814072,725442
    LT Debt, Non Current19.3%1,4801,2412021,2881,295
Shareholder's Equity-12.2%4,6555,3035,8866,2433,357
  Retained Earnings-11.1%-6,635.01-5,971.83-5,400.38-4,966.10-4,380.45
  Additional Paid-In Capital0.8%11,45211,35711,26811,1917,725
Accumulated Depreciation5.0%150143138124110
Shares Outstanding0.0%1,3501,3501,3351,3351,213
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-4.1%-1,686.27-1,620.07-1,660.38-1,298.72-1,123.22
  Share Based Compensation4.0%288277260241227
Cashflow From Investing18.8%1,148966559641445
Cashflow From Financing0.3%3,4763,4653,5183,637578

Risks

What is the probability of a big loss on BGNE?

100%


Probability that BeiGene stock will be more than 20% underwater in next one year

60%


Probability that BeiGene stock will be more than 30% underwater in next one year.

31.5%


Probability that BeiGene stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BGNE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BeiGene was unfortunately bought at previous high price.

Returns

Cumulative Returns on BGNE

20.0%


5-Year Cumulative Returns

0.3%


3-Year Cumulative Returns

What are the long-term rolling returns for BGNE?

FIve years rolling returns for BeiGene.

Which funds bought or sold BGNE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
-457
1,000
-%
2022-11-22
Seaport Global Advisors, LLC
-
-
-144,000
223,000
0.91%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-226,000
1,733,000
-%
2022-11-21
FourThought Financial, LLC
-
-
-2,000
6,000
-%
2022-11-18
National Pension Service
REDUCED
-7.13
-359,000
1,289,000
-%
2022-11-16
Front Row Advisors LLC
NEW
-
2,000
2,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-3,000
-
-%
2022-11-15
Clearstead Advisors, LLC
UNCHANGED
-
-9,000
40,000
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
5,000
-%
2022-11-15
STATE STREET CORP
REDUCED
-3.27
-24,100,000
99,989,000
0.01%

1–10 of 46

Latest Funds Activity

Are funds buying BGNE calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BGNE

BeiGene News

Seeking Alpha

BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns.9 hours ago

The Motley Fool

BGNE Fair Value

Recent SEC filings of BeiGene

View All Filings
Date Filed Form Type Document
Nov 30, 2022
4
Insider Trading
Nov 22, 2022
8-K
Current Report
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 09, 2022
10-Q
Quarterly Report
Nov 09, 2022
8-K
Current Report
Nov 07, 2022
8-K
Current Report
Oct 14, 2022
8-K
Current Report
Sep 22, 2022
4
Insider Trading
Sep 22, 2022
8-K
Current Report

Latest Insider Trading transactions for BGNE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-28
Wang Xiaodong
GIFTED
-
-
-52,000
-
2022-11-15
OYLER JOHN
SOLD
-1,019,230
206.824
-4,928
Chief Executive Officer
2022-11-15
OYLER JOHN
SOLD
-5,171,100
206.844
-25,000
Chief Executive Officer
2022-11-15
Wang Xiaodong
SOLD
-417,541
210.137
-1,987
-
2022-09-21
OYLER JOHN
SOLD
-2,776,640
149.845
-18,530
Chief Executive Officer
2022-09-20
OYLER JOHN
SOLD
-4,669,360
153.497
-30,420
Chief Executive Officer
2022-09-06
Wang Xiaodong
GIFTED
-
-
-33,410
-
2022-08-22
Yi Qingqing
SOLD
-
-
-7,800
-
2022-08-22
HHLR ADVISORS, LTD.
ACQUIRED
-
-
7,800
-
2022-08-08
Wang Xiaodong
SOLD
-1,219,590
201.253
-6,060
-

1–10 of 50

John V. Oyler
8200
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.

BGNE Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues    
Total revenues$ 387,628$ 206,440$ 1,035,826$ 962,304
Expenses    
Cost of sales - product76,54347,413212,953116,361
Research and development426,363351,9371,194,4851,028,754
Selling, general and administrative322,892269,227948,868683,622
Amortization of intangible assets187188563563
Total expenses825,985668,7652,356,8691,829,300
Loss from operations(438,357)(462,325)(1,321,043)(866,996)
Interest income (expense), net12,759(2,230)34,261(11,275)
Other (expense) income, net(125,640)31,477(243,290)26,487
Loss before income taxes(551,238)(433,078)(1,530,072)(851,784)
Income tax expense6,3185,03628,40815,354
Net loss$ (557,556)$ (438,114)$ (1,558,480)$ (867,138)
Net loss per share, basic (in dollars per share)$ (0.41)$ (0.36)$ (1.16)$ (0.72)
Net loss per share, diluted (in dollars per share)$ (0.41)$ (0.36)$ (1.16)$ (0.72)
Weighted average shares outstanding—basic (in shares)1,345,303,7471,205,971,2841,337,976,8531,196,391,201
Weighted average shares outstanding - diluted (in shares)1,345,303,7471,205,971,2841,337,976,8531,196,391,201
Net loss per American Depositary Share ("ADS") basic (in dollars per share)$ (5.39)$ (4.72)$ (15.14)$ (9.42)
Net loss per American Depositary Share ("ADS") diluted (in dollars per share)$ (5.39)$ (4.72)$ (15.14)$ (9.42)
Weighted-average ADSs outstanding - basic (in shares)103,484,90492,767,022102,921,29692,030,092
Weighted-average ADSs outstanding - diluted (in shares)103,484,90492,767,022102,921,29692,030,092
Product revenue, net    
Revenues    
Total revenues$ 349,506$ 192,461$ 915,590$ 437,202
Collaboration revenue    
Revenues    
Total revenues$ 38,122$ 13,979$ 120,236$ 525,102

BGNE Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS
¥ in Thousands, $ in Thousands
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Current assets:  
Cash and cash equivalents$ 4,197,132$ 4,375,678
Short-term restricted cash191328
Short-term investments871,9982,241,962
Accounts receivable, net189,170483,113
Inventories290,911242,626
Prepaid expenses and other current assets199,766270,173
Total current assets5,749,1687,613,880
Long-term restricted cash3,1896,881
Property, plant and equipment, net681,914587,605
Operating lease right-of-use assets110,340117,431
Intangible assets, net40,84946,679
Deferred tax assets00
Other non-current assets140,553163,049
Total non-current assets976,845921,645
Total assets6,726,0138,535,525
Current liabilities:  
Accounts payable252,071262,400
Accrued expenses and other payables410,255558,055
Deferred revenue, current portion144,984187,414
Tax payable22,66521,395
Operating lease liabilities, current portion24,34021,925
Research and development cost share liability, current portion115,721120,801
Short-term debt441,275427,565
Total current liabilities1,411,3111,599,555
Non-current liabilities:  
Long-term bank loans208,058202,113
Deferred revenue, non-current portion149,899220,289
Operating lease liabilities, non-current portion36,90443,041
Deferred tax liabilities15,24914,169
Research and development cost share liability, non-current portion204,252269,561
Other long-term liabilities45,16954,234
Total non-current liabilities659,531803,407
Total liabilities2,070,8422,402,962
Commitments and contingencies
Equity:  
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,349,640,180 and 1,334,804,281 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively135133
Additional paid-in capital11,451,56611,191,007
Accumulated other comprehensive (loss) income(161,523)17,950
Accumulated deficit(6,635,007)(5,076,527)
Total equity4,655,1716,132,563
Total liabilities and equity$ 6,726,013$ 8,535,525